Self-sustaining ROS-responsive hydrogel enabled delivery of PROTAC/Ce6 nanoparticles via PDT-Epigenetic protein degradation to amplify pyroptosis for enhanced cancer immunotherapy.
Aug 2026· Biomaterials· Vol 337, pp.
124600
· 0 citations· 70 references
Medicine
TL;DR
Experimental results validated that under laser irradiation, PACL@Gel demonstrated potent local tumor suppression and distant abscopal effect, prevented postoperative recurrence and established long-term immune memory, providing a robust and actionable approach to enhance PDT therapy in immunologically cold tumors combined with epigenetic strategies.
Abstract
Cancer immunotherapy exhibits limited efficacy in immunologically "cold" tumors due to insufficient T-cell infiltration and immunosuppressive tumor microenvironment. The efficacy of photodynamic therapy (PDT) is restricted by inadequate tumor-specific aggregation of photosensitizers and therapeutic resistance regulated by epigenetics. Herein, we engineered a light-driven, ROS-responsive hydrogel (PACL@Gel) for loading peptide-lipid scaffold nanoparticles encapsulating proteolysis targeting chimera (PROTAC) molecule and photosensitizer to enhance cancer immunotherapy. The system utilizes both endogenous and photodynamically amplified ROS to drive controlled hydrogel degradation and nanoparticle release, establishing a self-sustaining ROS feedback loop to overcome the limitations of insufficient endogenous ROS. The released PACL nanoparticles synergistically combine PDT with epigenetic BRD4 protein degradation to robustly amplify Caspase-3/GSDME dependent pyroptosis. Pyroptotic tumor cells would trigger immunogenic cell death, releasing inflammatory mediators and damage-associated molecular patterns that promote dendritic cells maturation and T-cell activation and infiltration to effectively remodel the immunosuppressive tumor niche and promote antitumor immunity. Experimental results validated that under laser irradiation, PACL@Gel demonstrated potent local tumor suppression and distant abscopal effect, prevented postoperative recurrence and established long-term immune memory. Collectively, this integrated PROTAC-PDT hydrogel platform effectively reprograms the immunosuppressive tumor microenvironment, providing a robust and actionable approach to enhance PDT therapy in immunologically cold tumors combined with epigenetic strategies.
A TME-adaptive platform that couples photothermal therapy with spatially confined STING activation is established, offering a mechanistically grounded strategy to overcome immune resistance in osteosarcoma.
Zhao-Long Yu, Qiu-Qun Xiao, Zhongyi Sun et al.· Photodiagnosis and Photodyna...· 0 citations
This hydrogel-nanoparticle composite platform helps overcome photothermal therapy-induced immune suppression, reduce oxidative stress in the TME, and inhibit tumor metastasis, offering a promising strategy for enhancing cancer immunotherapy.
Jie Sun, Yun-Yun Wu, Sheng Zhao et al.· ACS Applied Materials and In...· 0 citations
Photodynamic therapy (PDT) can elicit antitumor immunity by inducing immunogenic cell death (ICD), making it an attractive option for postoperative local cancer treatment. However, in solid tumors, aberrant vasculature and an immunosuppressive microenvironment often restrict immune-cell infiltration, thereby weakening...
A multifunctional hydrogel loaded with a novel cyanine nanozyme and Escherichia coli combines efficient photothermal therapy, photodynamic therapy, and peroxidase‐like enzyme activity to provide a novel and effective strategy for postoperative tumor therapy and recurrence inhibition.
Cong Jiang, Zi-Fan Yang, Rong Guo et al.· Advancement of science· 0 citations
This work developed a pH-responsive and cRGD-modified multifunctional liposomal system (FP2@PSLR) to co-deliver an immunogenic cytotoxic peptide and the PI3Kγ inhibitor IPI549 for coordinated TME remodeling, resulting in significant TME reprogramming.
This work presents an in situ-formed pH-responsive injectable hydrogel platform that integrates controlled drug release, Type I sonodynamic PANoptosis, and immune activation for enhanced antitumor immunotherapy.
Kexin Wen, Chenxi Zhang, Qin Fan et al.· Journal of Controlled Releas...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.